Friday, 16 October 2026European Markets

GROUPE JAJ Stock Went Down By Over 9% So Far On Tuesday

Loading stream...

groupe jaj, listed on the cac 40 as gjaj.pa, experienced its share price fall 9.03% by 11:52 am et tuesday to eur1.31. this drop follows two consecutive sessions of declines for this clothing distributor.

contradiction in market trends?

however, the overall cac 40 index experienced a modest gain of 0.16% to eur7,439.26, seemingly contradicting groupe jaj shares' downward momentum and showing that france remains on an upward trend despite groupe jaj stock value decline.

financial performance

groupe jaj, known for distributing schott brand clothing, reported 12-month earnings per share (eps) of eur0.24, signalling modest profitability for the firm. when considered alongside its price-to-earnings (p/e) ratio of 5.46, investors effectively paid eur5.46 per euro of groupe jaj's annual earnings when their shares were acquired.

investor sentiment

groupe jaj saw its trading volume for the day reach 8,255, an astonishing increase of 516.5% compared to its usual volume of 1,339. this sudden surge may signal investor fear about its future prospects and prompt increased selling action from shareholders.

important considerations for investors

investors would do well to pay attention to these events as they can provide a key window into the company's finances and market sentiment.

more news about groupe jaj (gjaj.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com